tetano
Editor, Senior Moderator
PLoS One
. 2023 Feb 9;18(2):e0276829.
doi: 10.1371/journal.pone.0276829. eCollection 2023.
SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients
Alev Celikgil[SUP] 1 [/SUP], Aldo B Massimi[SUP] 1 [/SUP], Antonio Nakouzi[SUP] 2 3 [/SUP], Natalia G Herrera[SUP] 1 [/SUP], Nicholas C Morano[SUP] 1 [/SUP], James H Lee[SUP] 1 [/SUP], Hyun Ah Yoon[SUP] 2 [/SUP], Scott J Garforth[SUP] 1 [/SUP], Steven C Almo[SUP] 1 [/SUP]
Affiliations
Abstract
Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) target multiple epitopes on different domains of the spike protein, and other SARS-CoV-2 proteins. We developed a SARS-CoV-2 multi-antigen protein microarray with the nucleocapsid, spike and its domains (S1, S2), and variants with single (D614G, E484K, N501Y) or double substitutions (N501Y/Deletion69/70), allowing a more detailed high-throughput analysis of the antibody repertoire following infection. The assay was demonstrated to be reliable and comparable to ELISA. We analyzed antibodies from 18 COVID-19 patients and 12 recovered convalescent donors. The S IgG level was higher than N IgG in most of the COVID-19 patients, and the receptor-binding domain of S1 showed high reactivity, but no antibodies were detected against the heptad repeat domain 2 of S2. Furthermore, antibodies were detected against S variants with single and double substitutions in COVID-19 patients who were infected with SARS-CoV-2 early in the pandemic. Here we demonstrated that the SARS-CoV-2 multi-antigen protein microarray is a powerful tool for detailed characterization of antibody responses, with potential utility in understanding the disease progress and assessing current vaccines and therapies against evolving SARS-CoV-2.
. 2023 Feb 9;18(2):e0276829.
doi: 10.1371/journal.pone.0276829. eCollection 2023.
SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients
Alev Celikgil[SUP] 1 [/SUP], Aldo B Massimi[SUP] 1 [/SUP], Antonio Nakouzi[SUP] 2 3 [/SUP], Natalia G Herrera[SUP] 1 [/SUP], Nicholas C Morano[SUP] 1 [/SUP], James H Lee[SUP] 1 [/SUP], Hyun Ah Yoon[SUP] 2 [/SUP], Scott J Garforth[SUP] 1 [/SUP], Steven C Almo[SUP] 1 [/SUP]
Affiliations
- PMID: 36757919
- DOI: 10.1371/journal.pone.0276829
Abstract
Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) target multiple epitopes on different domains of the spike protein, and other SARS-CoV-2 proteins. We developed a SARS-CoV-2 multi-antigen protein microarray with the nucleocapsid, spike and its domains (S1, S2), and variants with single (D614G, E484K, N501Y) or double substitutions (N501Y/Deletion69/70), allowing a more detailed high-throughput analysis of the antibody repertoire following infection. The assay was demonstrated to be reliable and comparable to ELISA. We analyzed antibodies from 18 COVID-19 patients and 12 recovered convalescent donors. The S IgG level was higher than N IgG in most of the COVID-19 patients, and the receptor-binding domain of S1 showed high reactivity, but no antibodies were detected against the heptad repeat domain 2 of S2. Furthermore, antibodies were detected against S variants with single and double substitutions in COVID-19 patients who were infected with SARS-CoV-2 early in the pandemic. Here we demonstrated that the SARS-CoV-2 multi-antigen protein microarray is a powerful tool for detailed characterization of antibody responses, with potential utility in understanding the disease progress and assessing current vaccines and therapies against evolving SARS-CoV-2.